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HEXTER 2 
ABSTRACT 
Fibroblasts, and their differentiation into myofibroblasts, are important in the pathology of 
several lung diseases including asthma and idiopathic pulmonary fibrosis (IPF). The 
differentiation process is dependent on several factors, such as soluble factors like transforming 
growth factor beta 1 (TGFβ1) and mechanical signals such as matrix stiffness. Additionally, the 
soluble arachidonic acid metabolite Prostaglandin E2 (PGE2) prevents TGFβ1 induced 
differentiation of fibroblasts to myofibroblasts, but the molecular mechanism is not completely 
understood15. Transient Receptor Potential Vanilloid 4 (TRPV4), a mechanosensitive ion 
channel, has previously been implicated in the differentiation of cardiac fibroblasts12,13. However, 
the role of TRPV4 in the differentiation of lung fibroblasts and its contribution to lung diseases 
such asthma has not been explored. Myofibroblasts express the contractile protein alpha smooth 
muscle actin (α-SMA) and are also distinguished by their excessive production of extracellular 
matrix (ECM) proteins such as fibronectin. The expression of α-SMA and ECM proteins has 
been shown to be mediated by serum response factor (SRF) and its co-activator myocardin 
related transcription factor (MRTF-A)5,6. Therefore, in the current project, we investigate 
differences in differentiation state between normal human lung fibroblasts (NHLF) and diseased 
human lung fibroblasts (DHLF). We show that DHLF have higher basal and increased α-SMA 
and fibronectin expression than NHLF, indicative of enhanced differentiation potential in DHLF. 
Additionally, we showed that lung fibroblast differentiation is regulated by TRPV4. 
Furthermore, we found that PGE2 inhibited TGFβ1-induced differentiation.  
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INTRODUCTION 
Fibroblasts play an important role in the wound healing process. When tissue injury 
occurs, transforming growth factor beta 1 (TGFβ1) promotes differentiation of fibroblasts into 
myofibroblasts, which deposit collagen and ECM proteins, including fibronectin, to help the 
wound heal1-3. Once differentiated, myofibroblasts can be distinguished by their expression and 
incorporation of alpha smooth muscle actin (α-SMA), a smooth-muscle contractile protein, into 
their stress fibers4. Serum response factor (SRF) and its co-activator myocardin related 
transcription factor (MRTF-A) mediates the fibroblast to myofibroblast differentiation process, 
subsequently upregulating fibrotic gene transcription (α-SMA expression as well as ECM 
protein secretion, including fibronectin)5,6.  
In contrast to the normal lung, in 
the 25,000,000 American patients with 
asthma, this wound healing process is 
uncontrolled and leads to increasing 
fibrosis and remodeling of the lung7,8. It 
affects a patient’s quality of life as well 
as costs the US billions in medical 
costs7. While TGFβ1 may appear to be an attractive target for treating pulmonary fibrosis (IPF) 
and asthma, blocking TGFβ1 signaling is not an effective solution due to TGFβ1’s numerous 
other roles in the body9.  
Fibroblast differentiation is dependent on both soluble factors such as TGFβ1 and 
mechanical signals such as matrix stiffness. Recently, TRPV4, a mechanosensor, has been shown 
to regulate TGFβ1-induced cardiac fibroblast differentiation. TRPV4 is a stretch-activated, non-
Figure 1. Structural topology of the TRPV4 mechanosensor (11). 
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selective ion channel that can integrate both mechanical and chemical stimuli. Structurally, 
TRPV4 contains six-transmembrane domains and an ankyrin repeat N-terminus domain. (Figure 
1)10. Hence, the TRPV4 receptor is a 
potential new therapeutic target for 
regulating pathological lung fibroblast 
differentiation.   
Similarly, Prostaglandin E2, 
(PGE2), a soluble arachidonic acid 
metabolite formed via the cyclooxygenase 
(COX) enzymatic pathway, prevents TGFβ1 induced differentiation of fibroblasts to 
myofibroblasts, thereby playing a protective role in fibroblast differentiation15. However, the 
molecular mechanism by which PGE2 exerts its inhibitory effect is not completely understood. 
PGE2 signals through four G-protein coupled receptors; namely, EP1-416- 18. EP receptor agonists 
are commercially available; specifically, iloprost (EP1), butaprost (EP2), and sulprostone 
(EP3/EP4)19-21.     
In this project, we investigated the differentiation potential of NHLF and DHLF with and 
without TGFβ1 treatment by examining the incorporation of the contractile protein, α-SMA, into 
stress fibers, as well as the expression of the ECM protein fibronectin and MRTF-A. Further, we 
investigated the role of TRPV4 in lung fibroblast differentiation and the molecular mechanism 
by which PGE2 exerts its protective effect in TGFβ1 induced lung fibroblast differentiation. 
 
 
 
 
Figure 1. Chemical structure of RN-1734 (22). 
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MATERIALS AND METHODS 
Reagents and Materials 
Normal human lung fibroblasts (CC-2512; Lonza, Walkersville, MD) and diseased 
human lung fibroblasts (00194912; Lonza, Walkersville, MD) were utilized for the experiments. 
Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA), Bovine 
Serum Albumin (BSA) from Fisher BioReagents (Fair Lawn, NJ), Dulbecco’s Modified Eagle’s 
Medium (DMEM) from Corning (Manassas, VA), penicillin and streptomycin from Invitrogen, 
culture plates and flasks from CytoOne, USA Scientific, Dulbecco’s Phosphate-Buffered Saline 
(DPBS) from Corning (Manassas, VA), 0.05% Trypsin-ETDA (1X) from Gilbco by Life 
Technologies Corporation (Grand Island, NY), Trypan Blue Solution, 0.4%, from Amresco 
(Solon, Ohio).   
RN-1734 was purchased from Tocris (Minneapolis, MN), TGFβ1 from R&D Systems 
(Minneapolis, MN); Prostaglandin E2  (PGE2), Prostaglandin D2 (PGD2), iloprost, butaprost and 
sulprostone all from Cayman Chemical Company, lysis buffer from BD Bioscience (San Jose, 
CA), protease inhibitor cocktail from Roche, phosphatase inhibitor cocktail from Pierce 
(Rockford, IL), Laemmli’s SDS-Sample Buffer (4X, reducing) from Boston BioProducts 
(Ashland, MA), 4% Paraformaldehyde in Phosphate-Buffered Saline from Boston BioProducts 
(Ashland, MA), 0.25% Triton X-100, SigmaUltra from Sigma-Aldrich (St. Louis, MO), 
phosphate buffered saline (PBS) tablets from Amresco Life Science, and Tween 20 from Fisher 
Scientific. 
 Mini-PROTEAN TGX Gels, 4-15%, were purchased from Bio-Rad Laboratories (USA), 
Western units from BioRad, Immobilon-FL Transfer Membranes from Merck (Darmstadt, 
Germany), chromatography paper from GE Healthcare UK Limited (Buckinghamshire, UK), 
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Transfer Buffer (10X) from Boston BioProducts (Ashland, MA), sodium dodecyl sulfate (SDS) 
from Sigma Life Science (St. Louis, MO), α-SMA antibody from Sigma-Aldrich (St. Louis, 
MO), secondary antibody from Jackson ImmunoResearch (West Grove, PA), fibronectin 
antibody from Abcam (Cambridge, MA), MRTF-A antibody from Santa Cruz Biotechnology 
(Santa Cruz, CA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody from 
Fitzgerald (Acton, MA), Nonfat Dry Milk from Quality Biological, Inc. (Landover, MD), 
Restore Western Blot Stripping Buffer from Thermo Scientific (Rockford, IL), Amersham ECL 
Western Blotting Detection Reagents from GE Healthcare (UK), Protein Simple from (San Jose, 
CA) and Alpha View, SA, from Protein Simple (St. Louis, MO).  
 
Cell Culturing 
NHLF and DHLF were cultured in 75 cm2 tissue culture flasks, in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/mL of 
penicillin/streptomycin, and 2mM L-glutamine, and were maintained at 37°C in a humidified 5% 
CO2 environment. Media was changed every 48 hours, and once cells were confluent, they were 
split via the following procedure: the media was aspirated, and they were washed with sterile 
Dulbecco’s Phosphate-Buffered Saline (DPBS). The DPBS was aspirated, trypsin was added, 
and the cells were incubated at 37°C in 5% CO2 for three minutes. 10% FBS in DMEM was 
added and used to wash any remaining cells off the plate and into solution. The solution was 
centrifuged and the media aspirated, and then the cells were resuspended in 10% FBS in DMEM. 
An equal amount of cells and the viability dye trypan blue were added to a hemacytometer and 
counted.  
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Cell Treatment 
For 24 hours prior to treatment, 75,000 (Western blotting) or 25,000 (immunostaining) 
cells per well were cultured in serum-free media (DMEM supplemented with 0.4% FBS, 100 
units/mL of penicillin/streptomycin, 2mM L-glutamine and maintained at 37°C in a humidified 
5% CO2 environment). Following serum starvation, cells were treated in 1% bovine serum 
albumin (BSA) in DMEM, supplemented with 100 units/mL of penicillin/streptomycin, 2mM L-
glutamine and maintained at 37°C in a humidified 5% CO2 environment, for 48 hours before 
lysis. TGFβ1 was used at a concentration of 2ng/ml. For treatments with RN, concentrations 
used included 10μM, 30μM, or 50μM, as indicated. For experiments with PGE2, concentrations 
used included 1pM, 10pM, 100pM or 5μM, as indicated. For experiments with PGD2, 5μM was 
used. For experiments with iloprost (10μM), butaprost (5μM) and sulprostone (100nM), the cells 
were pretreated for 30 minutes prior to TGFβ1 stimulation.  
 
Immunostaining 
For immunostaining, 25,000 cells/well were added at a volume of 0.5 mL/well to 24 well 
cell culture plates. As described above, cells were treated for 48 hours before fixation. Cells were 
fixed in 2% paraformaldehyde at 4°C for 15 minutes. They were then washed with phosphate-
buffered saline (PBS) twice, and permeabilized for five minutes with 0.25% Triton X-100 in 
PBS. Following two washes with PBS, they were blocked with a complete medium, 10% FBS, 
for 30 minutes. The primary antibody was added for one hour at room temperature, and then 
washed twice with PBS. After that secondary antibody was added for 30 minutes at room 
temperature and washed with PBS twice, plates were imaged with a fluorescent microscope 
(EVOS, 20X magnification). 
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Cell Lysates and Western Blotting 
For western blots, 75,000 cells/well were added at a volume of 2.0 mL/well to six well 
cell culture plates. Following stimulation with respective treatments, cells were lysed. First, they 
were washed with PBS. Lysis buffer, which was supplemented with protease inhibitor cocktail 
and phosphatase inhibitor cocktail was added, and wells were scraped. 4x reducing buffer was 
added and cells were frozen at -20°C.  
To prepare the samples for western blotting, samples were heated on a heating block at 
100°C for 10 minutes, and were loaded into a 4-15% 15-well polyacrylamide gel and standards 
were loaded into the first and last well, and between wells if necessary. Gels were run at 100V 
for an hour and half in 1x running buffer, or when the blue marker ran off the bottom of the gel. 
Working in cold transfer buffer, the gels were placed face down on three pieces of filter paper, 
and the PVDF membrane, which had been charged in methanol, was placed on top, then covered 
with three additional pieces of filter paper and sandwiched together in a cassette.  
The cassette was loaded into the western unit with an ice pack, cold transfer buffer and a 
stir bar, and ran for 100V for an hour and a half, with ice around the entire unit. Membranes were 
then washed in PBS and placed in a 5% milk solution for one hour. Following blocking, 
membranes were incubated with specific primary antibodies (α-SMA, fibronectin, or MRTF-A) 
diluted in 1x TBS, 5% dry milk, 0.1% Tween-20 (1:1000) overnight at 4°C on shaker. 
The next day the membranes were washed in TBS-tween three times (15 minutes, then 10 
minutes twice) and then the secondary antibody (in 5% milk) was added for one hour. The 
membranes were once more washed in TBS-tween three times (15 minutes, then 10 minutes 
twice), and then placed in plastic heat-seal bags and covered with 2 mL each of the ECL 
developing mixture. After sitting for one minute covered with foil, the membranes were placed 
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in another heat-seal bag and the bands were visualized using imager (Protein Simple). 
Membranes were stripped and re-probed for GAPDH as a loading control. 
 
Statistical Analysis 
 Western blots were prepared for analysis via Alpha View SA. Band intensity was 
determined using Alpha View’s Multiplex Band Analysis tool. Intensity values were then 
analyzed in Microsoft Excel. Intensity values were standardized against their control and then 
averages were calculated between duplicates. Standard error was calculated. Significance was 
determined using Student’s t test. *P<0.05. 
 
RESULTS 
TRPV4 regulates TGFβ1-induced α-SMA expression 
 In order to determine the effect of TGFβ1 on α-SMA expression in NHLF and DHLF 
cells as well as the effects of TRPV4 inhibition on differentiation, western blot analysis for α-
SMA expression was performed on cells following treatment with the TRPV4 inhibitor RN 
(10μM, 30μM or 50μM) and TGFβ1 (2ng/ml) for 48 hours (Figure 3a). The quantitative analysis 
revealed that TGFβ1 increased α-SMA expression in both NHLF and DHLF cells (Figure 3b). 
Furthermore, it showed that DHLF cells had higher basal α-SMA levels. Additionally, both types 
of cells were inhibited in a dose dependent manner by RN. To examine any differences in the 
localization of α-SMA between NHLF and DHLF cells, immunostaining was performed 
following treatment with RN (10μM, 30μM or 50μM) and TGFβ1 (2ng/ml) for 48 hours (Fig. 
3c, d). This analysis revealed that both NHLF and DHLF cells expressed α-SMA in stress fibers 
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in the presence of TGFβ1. Both types of cells were inhibited by RN, although at 30μM the 
DHLF cells still had a few stress fibers remaining, compared to virtually none in NHLF cells. 
 
  
B. 
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Figure 3. Effect of TGFβ1 on α-SMA in NHLF and DHLF Cells. A. Western blot of α-SMA expression in NHLF and DHLF 
cells. B. Quantification of α-SMA expression in NHLF and DHLF cells. C. Immunostaining of NHLF cells (C) and DHLF (D) 
with anti-alpha SMA antibody DHLF cells. *P<0.05. 
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TRPV4 regulates TGFβ1 induced fibronectin expression 
 Since TGFβ1 increased α-SMA expression in both NHLF and DHLF cells, we 
investigated whether TGFβ1 would in turn increase the expression of the ECM protein 
fibronectin1-3. In order to determine this as well as the effects of TRPV4 inhibition on 
differentiation, western blot analysis for fibronectin expression was performed following 
treatment with the TRPV4 inhibitor, RN (10μM, 30μM or 50μM) and TGFβ1 (2ng/ml) for 48 
hours (Figure 4a). This analysis revealed that TGFβ1 increased fibronectin expression in both 
NHLF and DHLF cells (Figure 4b). Similarly, higher basal fibronectin levels were observed in 
DHLF compared to NHLF. Significantly, TRPV4 inhibitor RN, attenuated fibronectin 
expression in both NHLF and DHLF.  
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Figure 4. Effect of TGFβ1 on fibronectin in NHLF and DHLF Cells. A. Western blot of fibronectin expression in NHLF and 
DHLF cells. B. Quantification of fibronectin expression in NHLF and DHLF cells. *P<0.05. 
 
PGE2 inhibits TGFβ1 induced differentiation in normal fibroblasts and subsequent α-SMA 
expression at a high physiologic concentration 
 Just as TRPV4 inhibition can affect differentiation, PGE2 has been implicated in TGFβ1 
induced differentiation15. Therefore, we analyzed the inhibitory effect of PGE2 on α-SMA 
expression. To determine this, western blot analysis for α-SMA expression was performed 
following treatment with PGE2 (1pM, 10pM, 100pM or 0.5μM) and TGFβ1 (2ng/ml) for 48 
hours (Figure 5a). This analysis revealed that differentiation was not inhibited at 1pM, 10pM, or 
100pM, but was inhibited at 0.5μM. In addition, we examined if PGD2, another PG metabolite, 
would have any effect on TGFβ1 induced differentiation, as it has been reported that PGD2 may 
be responsible for inhibition of collagen secretion in lung fibroblasts24. We found that TGFβ1 
induced α-SMA expression was not affected by PGD2 (0.5μM).  
B. 
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Figure 5. Effects of increasing concentrations of PGE2 on TGFβ1-induced differentiation in NHLF cells. A. Western blot of 
α-SMA expression in NHLF cells.  
 
PGE2 inhibits fibronectin expression in TGFβ1-differentated NHLF cells 
 We further analyzed the effect of PGE2 on the expression of fibronectin. To determine 
this, western blot analysis for fibronectin expression was performed following treatment with 
PGE2 (0.5μM) and TGFβ1 (2ng/ml) for 48 hours (Figure 6a). This analysis revealed that PGE2 
inhibited the TGFβ1-induced differentiation and subsequent fibronectin production in NHLF 
cells (Figure 7b).  
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Figure 6. Effect of PGE2 on fibronectin expression in TGFβ1-induced differentiation of NHLF cells. A. Western blot of 
fibronectin expression in NHLF cells. B. Quantification of fibronectin expression in NHLF cells. *P<0.05. 
 
PGE2 inhibits MRTF-A in TGFβ1 induced NHLF cells 
Since PGE2 inhibited both α-SMA and fibronectin expression in response to TGFβ1 in 
NHLF cells, we examined if PGE2 could inhibit NHLF differentiation by inhibiting MRTF-A 
expression. MRTF-A, a transcription factor, has been shown to mediate fibrotic gene 
transcription5,6. To determine this, western blot analysis for MRTF-A expression was performed 
following treatment with PGE2 (0.5μM) and TGFβ1 (2ng/ml) for 48 hours (Figure 7a). This 
analysis revealed that PGE2 inhibits MRTF-A expression in TGFβ1 induced cells (Figure 7b). 
 
B. 
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Figure 7. Effect of PGE2 on MRTF-A expression in TGFβ1-induced differentiation of NHLF cells. A. Western blot of MRTF-
A expression in NHLF cells. B. Quantification of MRTF-A expression in NHLF cells.  
 
PGE2 may be acting through the EP3 receptor to inhibit TGFβ1 induced differentiation in 
NHLF cells 
 Finally, we were interested in determining which of the EP receptors PGE2 may be 
exerting its inhibitory effect through. There are four receptors in the EP family which PGE2 may 
work through, EP1-416-18. Western blot analysis for α-SMA expression was performed following 
treatment with PGE2 (0.5μM), EP receptor agonists [iloprost (10μM), butaprost (5μM) and 
sulprostone (100nM)], and TGFβ1 (2ng/ml) for 48 hours (Figure 8a, b). PGE2 reduced TGFβ1-
induced α-SMA expression. The same effect was not observed with the other EP receptor 
agonists∗*.  
                                                
** Cells treated with sulprostone were detached before lysis. 
B. 
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Figure 8. Effects of EP agonists on α-SMA Expression in TGFβ1-induced differentiation of NHLF cells. A. Western blot of 
α-SMA expression in NHLF cells. B. Quantification of α-SMA expression in NHLF cells. *P<0.05. 
 
B. 
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DISCUSSION 
Fibroblasts, and their differentiation into myofibroblasts, are important in the pathology of 
several lung diseases including asthma and IPF. The differentiation process is dependent on 
several factors, including chemical stimuli such as TGFβ1 induction and mechanical stimuli such 
as matrix stiffening. The arachidonic acid metabolite, PGE2, has been shown to have an 
inhibitory effect on lung fibroblast differentiation, but the molecular mechanism is not 
completely understood15. Previously, the differentiation of cardiac fibroblasts has been shown to 
be regulated by TRPV412,13. Once differentiated, the myofibroblasts display several important 
characteristics, including the incorporation of α-SMA into stress fibers and excessive production 
of ECM proteins such as fibronectin. In addition, the transcription factor MRTF-A has been 
shown to play a role in the differentiation process by mediating the expression of fibrotic genes 
such as α-SMA and fibronectin5,6.  
 This project focused on examining TGFβ1-induced differentiation in NHLF and DHLF 
cells. We determined that TGFβ1 increases α-SMA expression in both NHLF and DHLF cells. 
The contractile protein α-SMA is expressed in myofibroblasts and not in fibroblasts, indicating 
that TGFβ1 promotes differentiation. Furthermore, DHLF cells showed higher basal α-SMA and 
increased α-SMA incorporation into their stress fibers. This may indicate that DHLF cells are 
more responsive to TGFβ1 signaling as compared to NHLF cells, are more likely to differentiate 
into myofibroblasts, and therefore more readily display the disease pathology. Significantly, the 
specific TRPV4 antagonist, RN, inhibited α–SMA expression and incorporation into stress fibers 
in a dose-dependent manner. 
We also determined that TGFβ1 increases fibronectin expression in both NHLF and 
DHLF cells. Increased fibronectin expression indicates TGFβ1 induced fibroblast to 
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myofibroblast differentiation. Furthermore, we found that DHLF cells showed higher basal 
fibronectin (ECM) levels. This provides additional support that DHLF cells may be more 
responsive to TGFβ1 signaling as compared to NHLF cells and therefore differentiate more often 
into myofibroblasts and display the disease pathology more readily. Significantly, the specific 
TRPV4 antagonist, RN, also inhibited fibronectin expression in a dose-dependent manner. 
Interestingly, our results suggest that TRPV4 regulation may be a potential therapeutic target for 
asthma and other fibrotic lung diseases.  
 PGE2 has been shown to be an effective inhibitor of TGFβ1-induced differentiation15. In a 
study of NHLF cells, we found that PGE2 inhibits TGFβ1-induced differentiation in NHLF at 
0.5μM. Additionally, the role of PGD2 was studied. We determined that PGD2 did not appear 
have any effect on TGFβ1-induced differentiation.  
 Similarly, fibronectin, which is produced by myofibroblasts and secreted as part of the 
ECM, is inhibited by PGE2. This provides further support for PGE2’s role in inhibiting TGFβ1-
induced differentiation, and the subsequent incorporation of α-SMA into stress fibers as well and 
secretion of ECM proteins including fibronectin. Additionally, the role of MRTF-A as a 
mediator of fibroblast differentiation has been described5,6. We determined that MRTF-A 
expression, which is upregulated during the TGFβ1 treatment, was attenuated by PGE2 treatment. 
PGE2 plays an important role in inhibiting the fibroblast to myofibroblast differentiation process, 
and demonstrates its potential importance as a pharmacologic treatment for fibrotic lung diseases 
such as asthma. 
 We also investigated the molecular mechanism of the inhibitory effect of PGE2. PGE2 
signals through four EP receptors (EP1-4 16-18). The data indicates that PGE2 appears to be 
working through EP3, but this cannot be confirmed due to cell detachment.  
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 As research continues into understanding the response of diseased (asthma) cells to 
differentiation signals as well as the effects of inhibition with regards to the treatment of asthma, 
our work may indicate that DHLF cells are more likely to differentiate into myofibroblasts and 
therefore more readily display the disease pathology. In addition, our work implicates the 
inhibitory role of the TRPV4 inhibitor RN as well as PGE2’s inhibitory effect on NHLF cells.  In 
the future, examining the effect of PGE2 in DHLF cells and their differentiation and subsequent 
α-SMA, fibronectin and MRTF-A expression would be helpful to understand any other 
differences between NHLF and DHLF responses to TGFβ1-induced differentiation. Similarly, 
examining the effects of various EP agonists as well as antagonists in TGFβ1-induced 
differentiated DHLF cells would provide additional understanding on the nature of DHLF cells’ 
responses to TGFβ1. The information gained throughout this project may be used in future 
experiments in the lab and in research publications, to further the development of therapies for 
asthma.  
 
SAFETY APPENDIX 
Laboratory safety training was conducted by Farai Gombedza, the graduate student overseeing 
the project. Standard Personal Protective Equipment (PPE) was used, including gloves, hair 
pulled back, and jewelry removed, during experiments and when completing work in the cell 
culture hood. Cell culture reagents, tools and gloves were disinfected with ethanol before their 
use in the hood, and cell culture tools and waste were disposed of into biohazard bags or liquid 
waste containers. All work was conducted under the supervision of a graduate student in the lab, 
and general health and safety protocols were followed throughout the completion of the project.  
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